Portal de investigación
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
Fecha de publicación:
Fecha Ahead of Print:
Autores organización
Autores
- Hernández-Gómez C
- Correa A
- Radice MA
- Castañeda-Méndez P
- Jaime-Villalon DA
- Gales AC
- Munita JM
Grupos de investigación
Resumen
Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known ß-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active ß-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales. © 2022 by the authors.
Datos de la publicación
- ISSN/ISSNe:
- 2079-6382, 2079-6382
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 36009970
- Enlace a otro recurso:
- www.scopus.com
ANTIBIOTICS-BASEL Multidisciplinary Digital Publishing Institute (MDPI)
Citas Recibidas en Web of Science: 3
Citas Recibidas en Scopus: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- antimicrobial resistance; ceftolozane/tazobactam; Enterobacterales; Latin America; Pseudomonas aeruginosa
Proyectos asociados
Colonización como factor de riesgo asociado a la infección por Enterobacterales productores de carbapenemasas (CPE) en pacientes hospitalizados en unidades de cuidados intensivos (UCI) en dos instituciones de salud en Colombia
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
PCI-2022-11023 . 2022
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-585 . 2020
Caracterización Molecular de Aislamientos Resistentes a Ceftazidime Avibactam en Enterobacterales y Pseudomonas aeruginosa recolectados en cinco Países de América Latina. Molecular mechanisms leading to ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa collected from five Latin American countries
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-586 . 2020
Haciendo frente a la multidrogo resistencia en Klebsiella pneumoniae: dinámica y evolución de plásmidos portadores de carbapenemasa en un país endémico para KPC
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
2022
Estudio comparativo in vitro de Ceftriaxona-Sulbactam-EDTA y antibióticos comparadores contra bacilos Gram negativos productores de β-lactamasas
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-ID-2021-638 . 2022